Androgen suppression strategies for prostate cancer: Is there an ideal approach? - Abstract

Department of Urology, Wilmington VA Medical Center, 1601 Kirkwood Highway, Wilmington, DE, 19805, USA.

Androgen suppression therapy (AST) was first described in 1941 as a treatment of prostate cancer (PCa) and remains the mainstay of therapy in patients with hormone-naïve metastatic disease. It also is used in locally advanced or recurrent disease and in combination with radiation therapy in patients with higher-risk features. Several approaches to AST have been developed as a result of increased understanding of the pathways controlling testosterone production. Increased recognition of the side effects has resulted in strategies to minimize complications associated with AST. Attempts to reduce AST adverse effects include intermittent hormonal therapy and methods to reduce amount of intracellular androgens without reducing the circulating testosterone levels.

Written by:
Ismail M, Ferroni M, Gomella LG.   Are you the author?

Reference: Curr Urol Rep. 2011 Mar 8. Epub ahead of print.
doi: 10.1007/s11934-011-0178-0

PubMed Abstract
PMID: 21384154

UroToday.com Prostate Cancer Section